Psoriasis Clinical Practice Guidelines (AAD/NPF, 2021)

American Academy of Dermatology and the National Psoriasis Foundation

These are some of the highlights of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

March 01, 2021

Guidelines on the management and treatment of psoriasis with topical and alternative therapies, nonbiologic therapies, phototherapy, and biologic therapies were published in February 2021 by the American Academy of Dermatology and the National Psoriasis Foundation in the Journal of the American Academy of Dermatology.[1]

Topical & Alternative Treatments

Topical therapies, tools to assess the severity of psoriasis, and alterative/complementary medicines are addressed, as follows:

  • Topical corticosteroids - Recommended for plaque psoriasis in nonintertriginous areas

  • Steroid-sparing agents (eg, vitamin D analogs, tazarotene, and calcineurin inhibitors, alone or in combination with steroids) - Confer lower risk of steroid-induced adverse effects; alternate use with steroids is key to long-term management

  • Other topical agents (eg, salicylic acid, emollients, anthralin, coal tar) - Can be use alone or in combination with topical steroids

  • Topicals combined with biologic or systemic therapies - Help increase overall efficacy of therapy

  • Severity measurement tools - Physician’s Global Assessment and body surface area (clinical practice); Psoriasis Area Severity Index (clinical trials); Dermatology Life Quality Index, Psoriasis Symptom Inventory, and pruritus assessment (subjective symptoms and quality of life)

  • Alternative medicines and complementary therapies (no recommendations, owing to lack of evidence) - Traditional Chinese medicine, herbal therapies (eg, aloe vera, St. John’s wort), diet/dietary supplements (eg, fish oil, vitamin D, turmeric/curcumin, zinc, gluten-free diet), body/mind interventions (eg, hypnosis, stress reduction, meditation)

Nonbiological Therapies

Covered in the guideline are recommendations and efficacy and safety information on 12 oral systemic, nonbiologic medications, as follows:

  • Methotrexate - Moderate-to-severe psoriasis in adults

  • Apremilast - Moderate-to-severe psoriasis in adults

  • Cyclosporine - Severe, recalcitrant psoriasis; in addition, erythrodermic, generalized pustular psoriasis and/or palmoplantar psoriasis

  • Acitretin - Monotherapy or combination therapy with PUVA or UVB

  • Other nonbiologics (not FDA-approved for psoriasis) - Tofacitinib, hydroxyurea, mycophenolate mofetil, azathioprine, leflunomide, tacrolimus, and thioguanine


The following phototherapy options are discussed in the guideline, with regard to dosing regimen, efficacy, and adverse effects:

  • Narrowband UVB

  • Broadband UVB

  • Targeted UVB - Excimer laser, excimer light, targeted narrowband UVB light

  • PUVA - Topical, oral, bath

  • Photodynamic therapy

  • Grenz ray

  • Climatotherapy

  • Visible light

  • Goeckerman therapy (not a form of phototherapy)

  • Pulsed dye laser

Biological Medications

Treatment recommendations are offered on the following biologic agents, with FDA approval date in parentheses:

  • TNF inhibitors - Etanercept (4/30/2004), infliximab (9/27/2006), adalimumab (1/22/2008), certolizumab (5/27/2018)

  • IL-12/IL-23 inhibitor - Ustekinumab (9/25/2009)

  • IL-17 inhibitors - Secukinumab (1/21/2015), ixekizumab (3/22/2016), brodalumab (2/15/2017)

  • IL-23 inhibitors - Guselkumab (7/13/2017), tildrakizumab (3/21/2018), risankizumab (pending)

For more information, please go to Psoriasis and Plaque Psoriasis.

For more Clinical Practice Guidelines, please go to Guidelines.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.